Galapagos N.V. Asset Resilience Ratio
Galapagos N.V. asset resilience ratio. Galapagos N.V. (GLPG) has an Asset Resilience Ratio of 86.45% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GLPG defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Galapagos N.V. (2014–2025)
Asset resilience ratio of Galapagos N.V. from 2014 to 2025. This chart shows how Galapagos N.V.'s Asset Resilience Ratio has changed over time. Read GLPG liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Galapagos N.V.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Galapagos N.V. assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.92 Billion | 86.45% |
| Total Liquid Assets | €2.92 Billion | 86.45% |
Asset Resilience Insights
- Very High Liquidity: Galapagos N.V. maintains exceptional liquid asset reserves at 86.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galapagos N.V. Industry Peers by Asset Resilience Ratio
Compare Galapagos N.V.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Galapagos N.V. Asset Resilience Ratio by Year (2014–2025)
Galapagos N.V. asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Galapagos N.V..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 85.43% | €2.91 Billion ≈ $3.40 Billion |
€3.41 Billion ≈ $3.98 Billion |
+11.60pp |
| 2024-12-31 | 73.83% | €3.05 Billion ≈ $3.57 Billion |
€4.14 Billion ≈ $4.84 Billion |
-6.90pp |
| 2023-12-31 | 80.73% | €3.52 Billion ≈ $4.11 Billion |
€4.36 Billion ≈ $5.09 Billion |
+4.99pp |
| 2022-12-31 | 75.74% | €3.59 Billion ≈ $4.19 Billion |
€4.73 Billion ≈ $5.53 Billion |
+28.18pp |
| 2021-12-31 | 47.56% | €2.47 Billion ≈ $2.89 Billion |
€5.19 Billion ≈ $6.07 Billion |
-5.37pp |
| 2020-12-31 | 52.93% | €3.03 Billion ≈ $3.54 Billion |
€5.72 Billion ≈ $6.68 Billion |
-11.65pp |
| 2019-12-31 | 64.58% | €3.92 Billion ≈ $4.58 Billion |
€6.07 Billion ≈ $7.09 Billion |
+63.98pp |
| 2016-12-31 | 0.61% | €6.57 Million ≈ $7.68 Million |
€1.08 Billion ≈ $1.27 Billion |
-0.94pp |
| 2015-12-31 | 1.55% | €6.86 Million ≈ $8.02 Million |
€442.51 Million ≈ $517.35 Million |
-2.30pp |
| 2014-12-31 | 3.85% | €10.42 Million ≈ $12.18 Million |
€270.47 Million ≈ $316.20 Million |
-- |
About Galapagos N.V.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory no… Read more